ENLIVEN THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.9 USD | -2.41% |
|
+13.86% | +72.69% |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 570.4 | 1,146 | - | - |
| Enterprise Value (EV) 1 | 570.4 | 966.3 | 1,116 | 908.7 |
| P/E ratio | -6.89 x | -10.4 x | -8.27 x | -8.07 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | 45,851 x | 45,851 x |
| EV / Revenue | - | - | 44,640 x | 36,346 x |
| EV / EBITDA | -6.83 x | -8.03 x | -6.98 x | -4.66 x |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 41,212 | 46,805 | - | - |
| Reference price 2 | 13.84 | 24.49 | 24.49 | 24.49 |
| Announcement Date | 3/14/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 0.025 | 0.025 |
| EBITDA 1 | - | - | -83.53 | -120.4 | -159.9 | -195 |
| EBIT 1 | - | -38.79 | -83.53 | -113.2 | -139.8 | -173.2 |
| Operating Margin | - | - | - | - | -559,074.68% | -692,680% |
| Earnings before Tax (EBT) 1 | - | -37.66 | -71.58 | -101.2 | -131.4 | -163.1 |
| Net income 1 | -24.74 | -37.66 | -71.58 | -101.2 | -131.4 | -163.1 |
| Net margin | - | - | - | - | -525,774.68% | -652,248% |
| EPS 2 | -3.170 | -3.560 | -2.010 | -2.360 | -2.962 | -3.033 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 11/10/22 | 3/21/23 | 3/14/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -16.42 | -20.13 | -24.25 | -22.73 | -25.52 | -27.65 | -29.8 | -30.21 |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -14.72 | -16.72 | -20.77 | -19.37 | -23.91 | -25.18 | -26.8 | -28.31 |
| Net income 1 | -14.72 | -16.72 | -20.77 | -19.37 | -23.91 | -25.18 | -26.8 | -28.31 |
| Net margin | - | - | - | - | - | - | - | - |
| EPS 2 | -0.8000 | -0.4100 | -0.5100 | -0.4700 | -0.5667 | -0.6200 | -0.6733 | -0.6867 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 5/11/23 | 8/10/23 | 11/9/23 | 3/14/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | 180 | 30.3 | 238 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | - | - | 0.72 | 0.9 | 1.13 |
| Capex / Sales | - | - | - | - | 3,580% | 4,504% |
| Announcement Date | 11/10/22 | 3/21/23 | 3/14/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
24.49
USD
Average target price
34.33
USD
Spread / Average Target
+40.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +76.95% | 1.15B | |
| +2.93% | 108B | |
| -2.62% | 23.46B | |
| -14.60% | 21.72B | |
| -7.05% | 18.64B | |
| -38.55% | 17.45B | |
| -8.83% | 17.19B | |
| +5.51% | 13.99B | |
| +37.49% | 12.53B | |
| +329.39% | 8.81B |
- Stock Market
- Equities
- ELVN Stock
- Financials Enliven Therapeutics, Inc.